A5038569402- Glioma Diagnosis and Treatment
- MRI in cancer diagnosis
- Radiomics and Machine Learning in Medical Imaging
- Advanced MRI Techniques and Applications
- RNA modifications and cancer
- Brain Metastases and Treatment
- Cancer-related gene regulation
- Cancer, Hypoxia, and Metabolism
- Advanced Neuroimaging Techniques and Applications
- Peptidase Inhibition and Analysis
- Epigenetics and DNA Methylation
- Meningioma and schwannoma management
- Medical Imaging Techniques and Applications
- Lanthanide and Transition Metal Complexes
- Neuroblastoma Research and Treatments
- Neurofibromatosis and Schwannoma Cases
- Lung Cancer Treatments and Mutations
- MicroRNA in disease regulation
- Cancer-related cognitive impairment studies
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Chromatin Remodeling and Cancer
- Cancer Treatment and Pharmacology
- Sarcoma Diagnosis and Treatment
- Electron Spin Resonance Studies
University of California, Los Angeles
2016-2025
University of Minnesota
2025
Mayo Clinic
2025
UCLA Medical Center
2018-2024
Dana-Farber Cancer Institute
2012-2024
UCLA Health
2013-2024
Sylvester Comprehensive Cancer Center
2024
Johns Hopkins University
2024
Children's Tumor Foundation
2024
UCLA Jonsson Comprehensive Cancer Center
2008-2023
Background There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials assess target modulation, measure anti-tumor activity, and enrich trial population for patients who are more likely benefit. Small, molecularly focused studies offer promise of early definition optimal biologic dose patient population. Methods Findings Based on preclinical evidence that phosphatase tensin homolog deleted Chromosome 10 (PTEN)...
Purpose This open-label, prospective, multicenter single-arm phase II study combined bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma (GBM). The objectives were to determine efficacy this combination associated toxicity. Patients Methods Seventy patients GBM enrolled between August 2006 November 2008. received standard RT starting within 3 6 weeks after surgery concurrent administration daily TMZ biweekly BV. After...
Purpose Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1 R132MUT ) is frequent low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a marker for GBMs that arise by transformation from lower-grade gliomas, regardless of clinical history. To determine how arising with IDH1 differ other GBMs, we undertook comprehensive comparison patients presenting clinically primary GBM function mutation status. Patients and Methods In all, 618 treatment-naive 235 were...
Protein tyrosine kinases are important regulators of cellular homeostasis with tightly controlled catalytic activity. Mutations in kinase-encoding genes can relieve the autoinhibitory constraints on kinase activity, promote malignant transformation, and appear to be a major determinant response inhibitor therapy. Missense mutations EGFR domain, for example, have recently been identified patients who showed clinical responses therapy.Encouraged by promising activity epidermal growth factor...
Abstract Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions extracellular (EC) domain. Unlike lung cancers with EGFR kinase domain (KD) mutations, GBMs respond poorly to inhibitor erlotinib. Using RNAi, we show that GBM cells carrying EC display addiction. In contrast KD mutants found cancer, glioma-specific are inhibited by inhibitors target active conformation (e.g., erlotinib). Inhibitors bind inactive conformation,...
Purpose: To determine if apparent diffusion coefficient (ADC) histogram analysis can stratify progression-free survival in patients with recurrent glioblastoma multiforme (GBM) prior to bevacizumab treatment. Materials and Methods: The study was approved by the institutional review board HIPAA compliant; informed consent obtained. Bevacizumab-treated control (41 per cohort) diagnosed GBM were analyzed using whole enhancing tumor ADC histograms a two normal distribution mixture fitting curve...
<h3>BACKGROUND AND PURPOSE:</h3> Both <i>IDH1</i> mutation and <i>MGMT</i> promoter methylation are associated with longer survival. We investigated the ability of imaging correlates to serve as noninvasive biomarkers for these molecularly defined GBM subtypes. <h3>MATERIALS METHODS:</h3> MR from 202 patients was retrospectively assessed nonenhancing tumor edema among other features. mutational status were determined by DNA sequencing methylation-specific PCR, respectively. Overall survival...
Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently administered courses of the prodrug FC (extended-release 5-fluorocytosine) into antimetabolite 5-fluorouracil. Forty-five subjects with recurrent or progressive high-grade glioma were treated. The end points this phase 1, open-label, ascending dose, multicenter trial included safety, efficacy, and molecular profiling;...
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO 2–3 oligodendroglioma [1p19q codeleted, IDH- mutant], 2–4 mutant astrocytoma, 4 glioblastoma), intracranial and spinal ependymomas, medulloblastoma, limited extensive brain metastases, leptomeningeal non–AIDS-related primary lymphomas, metastatic spine tumors, meningiomas, cord tumors. information contained in algorithms principles sections are...
Histone 3 (H3) K27M-mutant diffuse midline glioma (DMG) has a dismal prognosis with no established effective therapy beyond radiation. This integrated analysis evaluated single-agent ONC201 (dordaviprone), first-in-class imipridone, in recurrent H3 DMG.
Patients with recurrent gliomas (n = 14) were treated bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, reductions evident as little therapy. Treatment seemed more effective for heterogeneously enhancing compared solidly tumor.
<b>Objective:</b> Bevacizumab has been shown to be effective in the treatment of recurrent glioblastoma combination with chemotherapy compared historic controls but not randomized trials. <b>Methods:</b> We conducted a retrospective analysis patients treated for bevacizumab vs control group patients, comparing progression-free survival (PFS) and overall (OS) between two groups, performed subgroup based on age performance status. Expression vascular endothelial growth factor (VEGF) was...
<h3>BACKGROUND AND PURPOSE:</h3> Tumor location is a significant prognostic factor in glioblastoma, which may reflect the genetic profile of tumor precursor cells. The purpose current study was to construct and analyze probabilistic radiographic atlases reflecting preoperative locations corresponding demographic, “-omic,” interventional phenotypes provide insight into potential niche glioblastoma cells origin. <h3>MATERIALS METHODS:</h3> Preoperative anatomic MR images 507 patients with de...
<h3>BACKGROUND AND PURPOSE:</h3> Currently it is difficult to predict tumor response anti-angiogenic therapy in individual patients. Our aim was determine if ADC histogram analysis can stratify progression-free and overall survival patients with newly diagnosed GBM treated "up-front" (ie, before recurrence) bevacizumab. <h3>MATERIALS METHODS:</h3> Up-front bevacizumab-treated control (<i>n</i> = 59 62, respectively) were analyzed by using an approach based on enhancing tumor....
Purpose To compare the capability to aid prediction of clinical outcome measures, including progression-free survival (PFS) and overall (OS), between volumetric estimates from contrast material–enhanced (CE) T1-weighted subtraction maps traditional segmentation in a randomized multicenter trial recurrent glioblastoma (GBM) patients treated with bevacizumab. Materials Methods All participating this study signed institutional review board–approved informed consent at their respective...
To determine the difference in gene expression between completely versus incompletely enhancing glioblastoma multiforme (GBM).Gene was determined for 52 newly diagnosed GBMs by using DNA microarrays, and relationship to enhancement pattern survival analyzed. This study approved institutional review board HIPAA compliant; informed consent obtained.Thirty-eight percent (20 of 52) were (IE). The eight genes increased more than twofold IE GBM when compared with (CE) GBM. Among these tight...
Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine FC), results preclinically local production of 5-fluorouracil, depletion immune-suppressive myeloid cells, and subsequent induction antitumor immunity. Recurrent high-grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months....
6-(18)F-fluoro-l-dopa ((18)F-FDOPA) measured with PET as a biomarker of amino acid uptake has been investigated in brain tumor imaging. The aims the current study were to determine whether degree (18)F-FDOPA tumors predicted grade and was associated proliferative activity newly diagnosed recurrent gliomas.Fifty-nine patients (40 men, 19 women; mean age ± SD, 44.4 12.3 y) (n = 22) or 37) gliomas underwent perioperatively. Tumor tissue obtained by resection biopsy all patients. Ki-67...